Gabriel A Vargas

US Patent:

20140065610, Mar 6, 2014

Filed:

Aug 21, 2012

Appl. No.:

13/590211

Inventors:

Laurent Essioux - Attenschwiller, FR
Carsten Horn - Basel, CH
Johann Karl - Peissenberg, DE
Peter Kastner - Muenchen, DE
Fabian Model - Penzberg, DE
Giuseppe Palermo - Basel, CH
Christina Rabe - Bad Heilbrunn, DE
Daniel Umbricht - Zuerich, CH
Gabriel Vargas - Thousand Oaks CA, US
Anne Vogt - Loerrach, DE

International Classification:

G01N 33/68
C12Q 1/68

US Classification:

435 611, 435 74

Abstract:

An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI.